Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta

Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta

Author Barros, Elizabete Ribeiro Autor UNIFESP Google Scholar
Saraiva, Gabriela L. Autor UNIFESP Google Scholar
Oliveira, Telma Palomo de Autor UNIFESP Google Scholar
Lazaretti-Castro, Marise Autor UNIFESP Google Scholar
Institution Universidade Federal de São Paulo (UNIFESP)
Abstract Pamidronate (PAM) infusion is the standard treatment in children with osteogenesis imperfecta (OI). Zoledronic acid (ZOL) is a bisphosphonate with higher potency and faster intravenous infusion, but its efficacy and safety has not been established for OI patients. We report an open-label, prospective, and randomized clinical analysis to study the safety and efficacy of ZOL compared with PAM in 23 children with OI. They were selected to receive PAM (PAM group), 1 mg/kg/day, over 2 days or ZOL (ZOL group), 0.025-0.05 mg/kg/day, over 2 days every 3-4 months according to their ages, during a 1-year follow-up. They were observed for clinical and biochemical parameters, side effects, bone mineral density (BMD), and fracture rate. After treatment, the PAM and ZOL groups average lumbar spine (LS) BMD increased by 51.8% (p=0.053) and 67.6% (p=0.003), respectively. Parallel improvement was seen in LS Z-score in the PAM and ZOL groups, with scores of -5.3 to -3.8 (p=0.032) and -4.8 to -2.3 (p=0.007), respectively. LS Z-score for the ZOL group at the end of treatment was higher compared with the PAM group but only a borderline significance (p=0.053). the total alkaline phosphatase (AP) in the ZOL group significantly decreased from baseline at third and fourth infusion (p=0.032). Mild side effects were similar in both groups, but no severe clinical symptoms were reported. in conclusion, the present study shows that the use of ZOL in the dosage and period studied was safe and efficient to promote a clinical and densitometric improvement, similarly to PAM. Further studies are needed to establish optimal dosing and long-term safety.
Keywords BMD
efficacy
osteogenesis imperfecta
pamidronate
zoledronic acid
Language English
Date 2012-06-01
Published in Journal of Pediatric Endocrinology & Metabolism. Berlin: Walter de Gruyter & Co, v. 25, n. 5-6, p. 485-491, 2012.
ISSN 0334-018X (Sherpa/Romeo, impact factor)
Publisher Walter de Gruyter & Co
Extent 485-491
Origin http://dx.doi.org/10.1515/jpem-2012-0016
Access rights Closed access
Type Article
Web of Science ID WOS:000309754800014
URI http://repositorio.unifesp.br/handle/11600/34982

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account